Is cagrilintide FDA-approved?

No. Cagrilintide is investigational and is not approved by the FDA, MHRA, Health Canada, or the TGA. Research-peptide vendors sell it for laboratory research only.

What is the half-life of cagrilintide?

Published clinical pharmacokinetic studies report a half-life of approximately 7–8 days (around 159–195 hours across the clinical dose range), supporting once-weekly dosing in trial protocols.

What dose of cagrilintide is used in research?

Clinical trial protocols use graduated dose escalation. Pepticker does not publish a dosing recommendation — refer to the published trial protocols for the specific schedule you are reproducing.

What is cagrilintide commonly stacked with?

In clinical research the most-discussed stack is cagrilintide plus semaglutide — the CagriSema combination — which targets both the amylin and GLP-1 axes for weight management.

Is cagrilintide legal?

Cagrilintide is sold for research use in the US, Canada, and the UK. In Australia it is TGA Schedule 4 and personal import is tightly controlled. Status is informational — not legal advice.

metabolic

Cagrilintide

Amylin analog for weight research

0 vendors tracked0 live pricesLast crawl: warming up

About

A long-acting amylin analog studied as a weight-loss compound, often in combination with semaglutide (CagriSema) in clinical research.

Also known as: AM833, CAG~4, Cagrilinitide, SA-4C, Peptide C, Peptide C – 10mg, OmA – 4p, OmA – 4p 15, OmA – 1c, OmA – 1c 5

Reconstitution calculator

For research purposes only. Not for human consumption. Always verify calculations independently.

VialPeptide mass in vial (mg)mgBacteriostatic water added (mL)mL

DoseDesired dose

Syringe

How reconstitution works · Understanding syringe units

Cost-per-dose recalculates as you adjust the calculator above.

§ Frequently asked

Common questions about Cagrilintide

What is cagrilintide?: Cagrilintide (AM833) is a long-acting amylin analog studied as a weight-loss compound, often in combination with semaglutide (the CagriSema combination) in clinical research.
Is cagrilintide FDA-approved?: No. Cagrilintide is investigational and is not approved by the FDA, MHRA, Health Canada, or the TGA. Research-peptide vendors sell it for laboratory research only.
What is the half-life of cagrilintide?: Published clinical pharmacokinetic studies report a half-life of approximately 7–8 days (around 159–195 hours across the clinical dose range), supporting once-weekly dosing in trial protocols.
What dose of cagrilintide is used in research?: Clinical trial protocols use graduated dose escalation. Pepticker does not publish a dosing recommendation — refer to the published trial protocols for the specific schedule you are reproducing.
What is cagrilintide commonly stacked with?: In clinical research the most-discussed stack is cagrilintide plus semaglutide — the CagriSema combination — which targets both the amylin and GLP-1 axes for weight management.
Is cagrilintide legal?: Cagrilintide is sold for research use in the US, Canada, and the UK. In Australia it is TGA Schedule 4 and personal import is tightly controlled. Status is informational — not legal advice.

Editorial summary of published research. Not medical advice. See /methodology for sourcing.

Research use only. The compounds listed on this page are not approved for human use through research-chemical channels. Nothing on this page is medical advice. Consult a qualified clinician before considering any peptide protocol. See affiliate disclosure and our scoring methodology.

Keep exploring

Common questions about Cagrilintide

More on Cagrilintide & related research